Thanks for that clarification, I thought it wasn't "approved" but it clearly is. I've always scrape VAERS for Palivizumab and Nirsevimab and you can see it's been involved in many VAERS Death reports. I created a pseudo vax name and type for it within my dashboard so I know where all the reports are that have documented Synagis/palivizumab in the history, other meds, previous vax fields, narrative, etc...
I find it interesting that it is the drug they used in the trials for Beyfortus and Clesrovimab-cfor as the comparator. I guess that is their starting point to getting approved if they can do better than them in trials.
Palivizumab is the first one. It was approved for use in 1998. Here is the approval letter.
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/palimed061998L.htm
Thanks for that clarification, I thought it wasn't "approved" but it clearly is. I've always scrape VAERS for Palivizumab and Nirsevimab and you can see it's been involved in many VAERS Death reports. I created a pseudo vax name and type for it within my dashboard so I know where all the reports are that have documented Synagis/palivizumab in the history, other meds, previous vax fields, narrative, etc...
I find it interesting that it is the drug they used in the trials for Beyfortus and Clesrovimab-cfor as the comparator. I guess that is their starting point to getting approved if they can do better than them in trials.
No Longer a Debate.
Have been in the vax quax treches for over 35 years. Doctorate level.
This issue is shop worn.
Health does not come from needles. End of discussion.
More and more about less and less is not a debate, its a waste of time.
Steve did not fare well when he thought he could debate Andrew Kaufman...
This one is also unmatched. Kirsch will have no problems.